The Syntegon Group, a leading strategic partner to the global pharmaceutical, biotech and food industries, reported results for fiscal year 2024. Driven by its newly introduced corporate strategy focused on growth, operational excellence, and long-term value creation, Syntegon achieved accelerated growth, strong profitability, and improved cash flow. Strategic initiatives launched in 2024 included targeted investments in portfolio expansion and innovation.
“In 2024, we embarked on a new chapter of accelerated growth and value creation,” says Torsten Türling, CEO of Syntegon. “We are building on the incredible talent of the people at Syntegon, and our customers highly value our lifecycle services and turnkey solution approach. With our new strategic focus, we are well positioned to capture the strong long-term growth fundamentals, in particular of the Pharma and Biotech sectors.”
In 2024, Syntegon increased order intake by 11% to 1.8 billion EUR, while revenues grew by 7%, reaching 1.6 billion EUR. The Group’s strong revenue performance led to significant improvements in EBITDA and cash flow. Operational excellence initiatives contributed significantly to margin improvement in 2024. Adjusted EBITDA increased by 15% and reached 222 million EUR, corresponding to an EBITDA margin of 14%, a 100 basis points increase compared to the previous year. Focused working capital management has driven a strong increase in cash flow.
The Pharma business was the strongest contributor to growth, with order intake up by 17% and revenue up by 11%. Pharma accounted for 58% of total orders in 2024. The Food business grew orders by 4% and revenues by 2%, representing 42% of total orders. The high-margin service business recorded double-digit sales growth and accounted for 39% of total revenue.
Eros Carletti, CFO of Syntegon, says, “At both the Group level and across most business units, we exceeded our financial targets. Our solid financial performance, strong cash flow, and robust balance sheet position us well to pursue further organic growth and strategic acquisitions, enabling us to continue expanding our capabilities.”
Outlook 2025
Based on a strong order book and the continued favorable industry dynamics, particularly in the pharmaceutical and biotech sectors, Syntegon expects sustained growth momentum in 2025. The increasing proportion of high-margin service business and the ongoing operational efficiency improvements are expected to yield further margin improvements in 2025.
